Join the Alzheimer's Disease group to help and get support from people like you.
Alzheimer's Disease News (Page 16)
Related terms: Presenile Dementia, SDAT, Senile dementia Alzheimer's Type, Alzheimers
Scientists Discover the Brain's Waste-Disposal System, With Clues to Alzheimer's Disease
TUESDAY, Oct. 8, 2024 – The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and Alzheimer’s disease, a new study finds. Advanced i...
Falls Requiring Medical Attention Tied to Later Dementia Diagnosis
WEDNESDAY, Oct. 2, 2024 – Falling is independently associated with an increased risk for subsequent dementia diagnosis among older adults, according to a study published online Sept. 30 in JAMA ...
Air Pollution Could Be Changing Children's Brains
THURSDAY, Oct. 3, 2024 – Even air pollution levels considered safe by U.S. standards appear to cause differences in the brains of growing children, a new review suggests. "We're seeing differences...
Falling Linked to Raised Risk of Dementia in Older People
MONDAY, Sept. 30, 2024 – More than 14 million seniors a year take a tumble, and those falls can be life-changing. "The relationship between falls and dementia appears to be a two-way street," said ...
Synthetic THC May Calm Agitation in Alzheimer's Patients
MONDAY, Sept. 30, 2024 – A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer's, new research shows. Synthetic THC (dronabinol) also gave patients'...
Adverse Brain Health Outcomes Increased for Sexual, Gender Minority Groups
FRIDAY, Sept. 27, 2024 – Sexual and gender-minority (SGM) persons have increased odds of adverse brain health outcomes, according to a study published online Sept. 25 in Neurology. Shufan Huo, M.D.,...
Greater Adherence to MIND Diet Linked to Reduced Cognitive Impairment
WEDNESDAY, Sept. 18, 2024 – Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet adherence is associated with a reduced risk for...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 – For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease...
Cognitively Stimulating Leisure Activity Protects From Further Cognitive Decline
THURSDAY, Sept. 19, 2024 – High levels of cognitively stimulating leisure activity (CSLA) in older adults with mild cognitive impairment (MCI) can slow further decline, according to a study recently...
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
THURSDAY, Sept. 19, 2024 – A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inh...
FDA Approves Zunveyl (benzgalantamine) for the Treatment of Alzheimer's Disease
VANCOUVER, B.C., and Dallas, July 29, 2024 - Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilit...
FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease
INDIANAPOLIS, July 2, 2024 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's ...
FDA Grants Traditional Approval for Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas...
FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with Leqembi™ Treatment with Leqembi should be initiated in patients with mild c...
FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
BOSTON, March 14, 2022 /PRNewswire/ – Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,...